For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241010:nRSJ7452Ha&default-theme=true
RNS Number : 7452H Cambridge Cognition Holdings PLC 10 October 2024
10 October 2024
Cambridge Cognition Holdings plc
("Cambridge Cognition", the "Company" or the "Group")
Block Listing Return
The Company makes the following notification pursuant to AIM Rule 29 and
Schedule Six of the AIM Rules for Companies, regarding its existing block
listings:
Name of applicant: Cambridge Cognition Holdings plc
Name of scheme: Share Options
Period of return: From: 1 April 2024 To: 1 October 2024
Number and class of share(s) (amount of stock / debt securities) originally 1,000,000 ordinary shares of £0.01 each in the Company admitted to trading on
listed and the date of admission: 23 March 2023
Balance of unallotted securities under scheme(s) from previous return: 466,316 ordinary shares
Plus: The amount by which the block scheme(s) has been increased since the Nil
date of the last return (if any increase has been applied for):
Less: Number of securities issued/allotted under scheme(s) during period: Nil
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 466,316 ordinary shares
Name of contact: Simon McKeating
Telephone number of contact: +44 (0)1223 810700
Enquiries:
Cambridge Cognition Holdings plc c/o Hudson Sandler
Dr Steven Powell, Chairman
Hudson Sandler (Financial PR and IR) Tel: 020 7796 4133
Dan de Belder / Hattie Dreyfus cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)
Panmure Liberum Limited (NOMAD and Joint Broker) Tel: 020 7886 2968
Will Goode / Freddy Crossley / Mark Rogers (Corporate Finance)
Rupert Dearden (Corporate Broking)
Dowgate Capital Limited (Joint Broker) Tel: 020 3903 7715
David Poutney / Nick Chambers
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.
For further information visit: https://cambridgecognition.com/
(https://cambridgecognition.com/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END BLREAFEEFLDLFFA